Table 4.
Hemodynamic Parameters and NT-proBNP Concentrations in Patients Administered Macitentan 10 mg (n=9)
| Mean±SD | Median | IQR | |
|---|---|---|---|
| Cardiac output (L/min) | |||
| Baseline | 3.1±0.9 | 3.2 | 2.6, 3.8 |
| Week 16 | 4.0±2.1 | 3.4 | 2.4, 4.7 |
| Change from baseline at Week 16 | 0.8±1.5 | 0.2 | 0.1, 1.5 |
| Cardiac index (L/min/m2) | |||
| Baseline | 2.1±0.5 | 2.1 | 1.8, 2.4 |
| Week 16 | 2.7±1.3 | 2.3 | 1.5, 3.6 |
| Change from baseline at Week 16 | 0.6±0.9 | 0.1 | 0.1, 1.1 |
| mPAP (mmHg) | |||
| Baseline | 35.8±6.7 | 35.0 | 30.0, 41.0 |
| Week 16 | 31.8±8.7 | 33.0 | 26.0, 37.0 |
| Change from baseline at Week 16 | −4.0±7.4 | −6.0 | −7.0, −4.0 |
| mRAP (mmHg) | |||
| Baseline | 4.7±2.7 | 5.0 | 3.0, 7.0 |
| Week 16 | 4.6±2.6 | 5.0 | 3.0, 6.0 |
| Change from baseline at Week 16 | −0.1±2.7 | 0.0 | −2.0, 1.0 |
| PAWP (mmHg) | |||
| Baseline | 7.6±2.8 | 8.0 | 4.0, 10.0 |
| Week 16 | 8.2±2.9 | 9.0 | 8.0, 10.0 |
| Change from baseline at Week 16 | 0.7±2.4 | 1.0 | −1.0, 2.0 |
| SvO2 (%) | |||
| Baseline | 65.9±7.3 | 67.0 | 58.2, 70.4 |
| Week 16 | 66.2±13.3 | 65.6 | 57.0, 69.0 |
| Change from baseline at Week 16 | 0.3±11.8 | −0.2 | −7.8, 1.6 |
| TPR (dyn·s·m2/cm5) | |||
| Baseline | 988.2±415.5 | 869.6 | 819.1, 1,043.5 |
| Week 16 | 808.1±495.4 | 610.2 | 456.8, 1,048.0 |
| Change from baseline at Week 16 | −180.1±251.1 | −254.4 | −315.2, −213.9 |
| NT-proBNP (pg/mL)A | |||
| Baseline | 746.4±1,447.1 | 226.0 | 129.0, 345.0 |
| Week 16 | 213.8±223.6 | 146.5 | 45.0, 308.0 |
| Change from baseline at Week 16 | −55.5±86.9 | −78.0 | −105.5, −31.0 |
A The number of patients analyzed was 9, 8, and 8 at baseline, Week 16, and for the change from baseline at Week 16, respectively. IQR, interquartile range; mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial pressure; NT-proBNP, N-terminal pro B-type natriuretic peptide; PAWP, pulmonary arterial wedge pressure; SvO2, mixed venous oxygen saturation; TPR, total pulmonary resistance.